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Abstract
Peptide probes for imaging retinal ganglion cell (RGC) apoptosis consist of a cell-penetrating peptide targeting moiety and
a fluorophore-quencher pair flanking an effector caspase consensus sequence. Using ex vivo fluorescence imaging, we
previously validated the capacity of these probes to identify apoptotic RGCs in cell culture and in an in vivo rat model of N-
methyl- D-aspartate (NMDA)-induced neurotoxicity. Herein, using TcapQ488, a new probe designed and synthesized for
compatibility with clinically-relevant imaging instruments, and real time imaging of a live rat RGC degeneration model, we
fully characterized time- and dose-dependent probe activation, signal-to-noise ratios, and probe safety profiles in vivo.
Adult rats received intravitreal injections of four NMDA concentrations followed by varying TcapQ488 doses. Fluorescence
fundus imaging was performed sequentially in vivo using a confocal scanning laser ophthalmoscope and individual RGCs
displaying activated probe were counted and analyzed. Rats also underwent electroretinography following intravitreal
injection of probe. In vivo fluorescence fundus imaging revealed distinct single-cell probe activation as an indicator of RGC
apoptosis induced by intravitreal NMDA injection that corresponded to the identical cells observed in retinal flat mounts of
the same eye. Peak activation of probe in vivo was detected 12 hours post probe injection. Detectable fluorescent RGCs
increased with increasing NMDA concentration; sensitivity of detection generally increased with increasing TcapQ488 dose
until saturating at 0.387 nmol. Electroretinography following intravitreal injections of TcapQ488 showed no significant
difference compared with control injections. We optimized the signal-to-noise ratio of a caspase-activatable cell penetrating
peptide probe for quantitative non-invasive detection of RGC apoptosis in vivo. Full characterization of probe performance
in this setting creates an important in vivo imaging standard for functional evaluation of future probe analogues and
provides a basis for extending this strategy into glaucoma-specific animal models.
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Introduction
Molecular imaging utilizing peptide probes provides a non-
invasive means for interrogating cells in vivo for a specific
intracellular biochemical event [1,2]. Activatable probes denote
such events via enzyme-specific cleavage, resulting in a detectable
signal [3,4]. Through an intramolecular optical quenching
strategy, activatable probes with a fluorescent signal moiety
remain optically silent until activation by the target enzyme. This
probe design confers a high degree of specificity and maximizes
the signal-to-noise ratio for optimal detection of events that may
occur at a relatively low frequency. This strategy is particularly
attractive for application to the eye, as optical imaging can be
utilized to identify a fluorescent target using clinically available
instruments.
Apoptosis occurs in both normal development and disease in a
wide range of tissues and therefore is an attractive target for
molecular imaging [5,6]. Glaucoma, a leading cause of blindness,
is characterized by the selective degeneration of retinal ganglion
cells (RGC) via apoptosis [7,8,9,10]. Apoptosis can be identified
through the activity of the caspase family of proteases, which plays
a central role in the enzymatic pathway leading to apoptotic cell
death [11,12]. Previously, we described the design and validation
in vitro of cell-penetrating peptide probes sensitive to activated
effector caspase activity [3,13,14,15,16]. Intracellular delivery of
these molecular imaging probes was enabled through conjugation
to a cell-penetrating peptide sequence serving as a targeting moiety
to facilitate rapid probe translocation into cells via endocytic
pathways [17]. We demonstrated highly specific uptake by RGCs
following intravitreal injection of fluorophore conjugated to our
modified cell-penetrating peptide sequence [13], and subsequently
utilized these probes in a rat model of NMDA-induced RGC
degeneration to validate probe activity and localization ex vivo
[18,19].
PLOS ONE | www.plosone.org 1 February 2014 | Volume 9 | Issue 2 | e88855
Using the rat NMDA model, herein we fully characterized
probe activation in vivo using a confocal scanning laser ophthal-
moscope (CSLO) and a clinically-relevant protocol. This approach
enabled repetitive and sequential non-invasive fluorescence fundus
imaging of individual animals to determine the temporal course of
probe activation in vivo, the optimal kinetics of probe delivery, and
a probe dose providing an optimal signal-to-noise ratio in this
model. In addition, electroretinogram (ERG) studies were
performed to rule out probe-related toxicity. These studies provide
a rational basis for future structure-function probe evaluation and
for extending these probes and strategies to more disease-specific




All animal experiments were approved by the Institutional
Animal Care and Use Committee at Washington University in St.
Louis School of Medicine and adhere to the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research. Male
Brown Norway rats weighing approximately 200 g each were
purchased from Harlan Laboratories (Indianapolis, IN). All
experiments were performed in triplicate or more.
Activatable Cell-penetrating Peptide (TcapQ488)
TcapQ488 was produced and purified using methods as
previously described [17,18]. This activatable peptide probe
consists of an all D-amino acid modified Tat cell-penetrating
peptide, an L-amino acid effector caspase recognition sequence
(DEVD), a quencher (QSY7), and a fluorophore (Alexa Fluor-
488). This particular fluorophore was chosen for compatibility
with clinically-available fluorescent fundus imaging instruments,
which are designed for use with either fluorescein or indocyanine
green. Upon cleavage of the effector caspase recognition sequence
and subsequent loss of fluorescent quenching, fluorescence from
the retained intracellular fluorophore is detectable via fluorescence
imaging. Stock solutions of purified peptides were formulated in
milliQ water at various concentrations and stored at 220uC.
Intravitreal Injections
All probe, PBS, and NMDA intravitreal injections were
performed as described [18,19]. Briefly, rats were anesthetized
by isoflurane inhalation or intraperitoneal injection (0.10 ml/
100 g) of a cocktail containing 2 ml ketamine (100 mg/ml), 1.5 ml
xylazine (20 mg/ml) and 0.5 ml isotonic sterile saline. Intravitreal
injections were performed under a microscope with a U-100 29
gauge, K inch length insulin needle and a co-axial 33 gauge, 1
inch length blunt metal needle on a 2.5 ml Hamilton syringe
(Hamilton Company, NV). The eye was first punctured by the 29
gauge needle at approximately 1 mm behind the limbus on the
nasal side of the eye, aiming toward the optic nerve head. The 33
gauge needle on the 2.5 ml Hamilton syringe was then inserted
into the eye through the puncture to deliver injectate. Caution was
taken to deliver injectate slowly, over approximately 3 minutes.
Erythromycin ointment was applied topically after each intraoc-
ular injection.
In experimental groups, eyes were pretreated by injecting 2 ml
of 2.5, 12.5, 25 or 40 mM (corresponding to 5, 25, 50 and
80 nmol, respectively) NMDA (Sigma, St. Louis, MO) prepared in
0.01 M phosphate buffered saline (PBS, pH 7.4). Twenty-four
hours later, 2.5 ml of 0.039, 0.078, 0.125, 0.155 or 0.310 mM
TcapQ488 in PBS were injected into the vitreous. In control
experiments, eyes were pretreated with 2 ml of 0.01 M PBS instead
of NMDA and followed by 2.5 ml TcapQ488 injection. Animals
with visible lens damage, vitreous or retinal hemorrhage or retinal
detachment were excluded from analysis, although this was a rare
occurrence.
In Vivo Imaging
A CSLO (Retinal Angiograph II, Heidelberg Engineering, Inc.,
Germany) equipped with a 55u field of view (FOV) lens was used
for in vivo image acquisition. Rat retinas were typically imaged at
4, 12, 24, 48 and 72 hours post probe injection. Rats were
positioned on a platform attached to the CSLO chin rest. A
custom-made PMMA contact lens (Cantor & Nissel Limited,
Brackley, UK) was placed on the eye for all imaging to protect the
corneal surface and improve image quality. Pupils were dilated
with one drop of Tropicamide ophthalmic solution USP 1%
(Bausch & Lomb, Tampa, FL). The CSLO image was focused on
the retinal nerve fiber layer under infrared reflection mode (IR,
diode laser at 820 nm) at 50% intensity to center the optic disc in
the image (Figure 1A). Fluorescent angiograph mode (FA, blue
solid laser at 488 nm with 500 nm barrier filter) was then used to
acquire activated TcapQ488 fluorescence signal of the RGC layer
(Figure 1B). All CSLO images were recorded as an average of 100
aligned frames to obtain a single low-noise, high contrast image.
Ex Vivo Imaging
Retinal flat mounts were prepared and fluorescence microscopy
performed as described previously [18].
Image Analysis and Cell Counting
Images used for data analysis/cell counting were centered at the
optic disc. Imaging parameters, including gain, were kept constant
during image acquisition. Fluorescence signals were counted
manually using Image J software [20] based on fluorescence
intensity and sharpness. Manual counting enabled consistent and
accurate analysis throughout cell counting. Quantitation by
manual counting was confirmed in a subset of animals using
‘‘Find Maxima’’, an automated cell counting program in ImageJ
(http://rsb.info.nih.gov/ij); noise tolerance was set at 17, edge and
center (optic disc) maxima were excluded from the analysis field
(See Figure S1).
Electroretinography (ERG) Protocol
Rats were dark-adapted overnight, prepared for recording
under dim red illumination, and anesthetized initially by
subcutaneous injection of ketamine/xylazine cocktail (0.10 ml/
100 g) containing 2 ml ketamine (100 mg/ml), 1.5 ml xylazine
(20 mg/ml) and 0.5 ml isotonic sterile saline and supplemented as
necessary at 1/4 of the original dose. Pupils were dilated with
1.0% atropine sulfate ophthalmic solution (Bausch & Lomb,
Tampa, FL). During testing, a heating pad controlled by a rectal
temperature probe maintained body temperature between 36.5uC
and 37.5uC. Each rat was positioned with its head just inside the
opening of a Model 2503D Ganzfeld stimulator (LKC technol-
ogies, Gaithersburg, MD). ERGs were recorded using a platinum
loop electrode (2.0 mm in diameter) positioned in a drop of 0.5%
atropine sulfate in 1.25% hydroxypropyl methylcellulose (GO-
NAK; Akorn Inc., Buffalo Grove, IL) on the corneal surface of the
eye to be tested. A reference needle electrode was inserted under
the skin at the vertex of the skull and a ground electrode was
inserted under the skin of the back or tail. Flash ERG
measurements were performed with a UTAS-E3000 Visual
Electrodiagnostic System using EM for Windows software (LKC
Technologies, Inc., Gaithersburg, MD). The stimulus (trial)
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consisted of a brief full field flash (10 ms), either in darkness or in
the presence of dim (29 cd/mm) or bright (198 cd/mm)
background illumination after 10 minutes of light adaptation.
The initiation of the flash was taken as time zero. The response
was recorded over 250 ms plus 25 ms of pre-trial baseline.
Responses from several trials were averaged and the interval
between flash trials was adjusted so that responses did not decrease
in amplitude over the trial series of for each step. The log light
intensity (log [cd*s/m2]) was calculated based on the manufacturer’s
calibrations. To reduce noise interference, a 60 Hz digital notch
filter was used for weak responses (routinely for intensities below2
2 log; as needed for brighter intensities).
Rats underwent ERG testing pre-injection, at 1 week and at 2
months post intravitreal injection of TcapQ488. Probe concen-
trations of 0.078 mM and 0.155 mM in 2.5 ml (0.193 and
0.387 nmol, respectively) were examined. Control rats underwent
PBS injection only. All conditions were tested in triplicate.
Statistical Analyses
Data were analyzed using SAS version 9.3 (Base SASH 9.3,
Procedures Guide: Statistical Procedures, SAS Institute, Inc.,
Cary, NC, 2011). All p-values were two-tailed. A p-value ,0.05
was considered significant. An analysis of variance was performed
on the log transformed probe activation data to determine the
effect of eye, light intensity, probe dose, and NMDA concentration
on probe activation. Simple effects tests were done to determine
significant effects of probe dose at each NMDA concentration and
vice versa. For ERG data, a repeated measures analysis of variance
was used to determine the effect of eye, probe, and time on B-wave
amplitude. Significant interactions were followed-up with simple
effects tests for probe conditions and time periods. Significant
simple effects tests were further investigated using pair-wise
comparisons.
Results
Correspondence of In Vivo and Ex Vivo Imaging of Probe
Activation
Strong fluorescent signals were observed with in vivo imaging in
the RGC layer of eyes of living rats pretreated with NMDA
followed by TcapQ488 (Figure 1B). The fluorescence was cell-
specific and punctate, consistent with our previous ex vivo
observations that fluorescence was restricted to the cell bodies of
individual RGCs containing activated probe. Several eyes
underwent in vivo imaging followed by histological assessment of
retina flat mounts ex vivo to directly compare in vivo fluorescence
fundus images with ex vivo flat mount fluorescence microscopy
images of the same retina. Retinal flat mounts displayed distinct
fluorescent signals in individual cell bodies, consistent with probe
activation in a specific subset of cells. Comparison of in vivo and ex
vivo images revealed excellent correspondence of the same
individual fluorescent cell bodies (Figure 2). As documented
previously [18], vertical retinal sections confirmed that the vast
majority of fluorescent cell bodies, with the exception of a few cells
in the inner nuclear layer, were located within the RGC layer
(data not shown). Spread of fluorescence to the optic nerve
suggested that at least the cleavage product, in this case Alexa
Fluor 488, may enter axonal transport pathways in RGCs.
Probe Activation as a Function of Time
Following pre-treatment with NMDA and TcapQ488 injection,
serial in vivo fluorescence fundus imaging in individual animals
using the CSLO enabled clear delineation of the spatial and
temporal pattern of probe activation (Figures 3, 4). Animals were
routinely imaged immediately before probe injection and five
times post-probe injection (at 4, 12, 24, 48 and 72 hours) to
determine the kinetics of probe activation in vivo and the optimal
time point for detecting probe activation. TcapQ488 activation
was evident 4 hours post probe injection (Figures 3, 4). Notably,
stronger fluorescent signal was noted near the injection site,
Figure 1. In vivo confocal scanning laser ophthalmoscopic imaging of single retinal ganglion cell (RGC) apoptosis. (A) Infrared
reflection fundus image at 25 hours post-probe injection from a rat eye pretreated with 25 mM NMDA and followed 24 hrs later by injection of
0.387 nmol TcapQ488. The image was focused on the Nerve Fiber Layer using a 55uFOV lens. (B) Fluorescein angiograph (FA) mode fundus image
from the same eye at the same time point and focal plane showing distinct fluorescent signals from probe activation. Both images were recorded as
an average of 100 aligned frames to obtain a single low-noise, high contrast image. Scale bar in both images, 200 mm.
doi:10.1371/journal.pone.0088855.g001
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consistent with a subtle gradient effect reflecting diffusion of both
probe and NMDA throughout the vitreous from the injection site.
Figure 4A shows the time course of fluorescent probe activation
determined from analysis of the images from Figure 3B–F. Probe
activation increased significantly in the first 12 hours, remaining
relatively steady out to 72 hours. As expected, probe activation
signals were dependent on probe dose and NMDA concentration,
but this kinetic pattern was remarkably consistent across all probe
dose and NMDA concentration combinations (Figure S2).
Figure 4B represents a normalized analysis of probe activation
kinetics over the first 72 hours based on pooled data across the
study. From this kinetic analysis, the 12 hour time point was
utilized to quantify probe activation across all NMDA and probe
concentrations.
Probe Activation as a Function of NMDA Concentration
We previously determined the frequency of probe activation at
one single time point across multiple NMDA concentrations
through ex vivo analyses of retinal flat mounts [18]. Using the same
model and NMDA concentrations (2.5, 12.5, 25, 40 mM) with
in vivo imaging, we confirmed the NMDA concentration-response
relationship with probe activation at multiple time points post-
probe injection (Figure 5). Control injections of PBS were also
performed to determine the background level of probe activation
in the absence of NMDA excitotoxicity. As expected, NMDA-
induced apoptosis, indicated by TcapQ488 activation in individual
RGCs, occurred in a dose-dependent manner as documented by
in vivo imaging. Significant interaction between probe and NMDA
was observed (p = 0.015) indicating that probe activation depend-
ed on NMDA concentration. There were significant differences in
probe activation among the four NMDA concentrations across all
probe doses (TcapQ488 dose (nmol): 0.097, p = 0.0001; 0.193, p,
0.0001; 0.313, p,0.0001; 0.387, p= 0.0064; 0.775, p,0.0001),
but not for PBS (PBS, p = 0.45). Increased probe activation was
observed with greater NMDA concentrations at nearly all probe
doses examined (Figures 6, 7), the exception being at 0.097 nmol
TcapQ488, where probe activation frequency was relatively small
for all four NMDA concentrations (pair-wise tests not performed)
(Figure 7). This was documented at all 5 time points examined (4,
12, 24, 48 and 72 hours post-probe injection), again with maximal
or near-maximal TcapQ488 activation observed at 12 hours post-
probe injection (Figures 5, S2).
Probe Signal as a Function of Probe Dose
To determine the probe concentration that maximized RGC
apoptosis detection while minimizing background probe signal,
five TcapQ488 doses (0.097, 0.193, 0.313, 0.387 and 0.775 nmol)
were examined at each standard NMDA concentration (Figures 6,
7, S2). TcapQ488 activation across probe doses for 25 mM
NMDA is shown in detail in Figure 6. As TcapQ488 dosage
increased, the probe activation frequency also increased, suggest-
ing that the sensitivity of TcapQ488 in detecting apoptosis using
our in vivo imaging strategy was dependent on probe dose. Figure 7
shows probe activation results for each combination of NMDA
concentration and TcapQ488 dosage at the 12 hour time point.
There were significant differences in activation frequency across
probe doses at all NMDA concentrations (2.5 mM, p=0.02;
12.5 mM, p= 0.002; 25 mM, p,0.001; 40 mM, p,0.001). Probe
activation generally increased as probe dose increased for each
NMDA concentration. The relationship between probe dose and
activation, however, began to saturate at higher probe doses
indicating that further increases would likely be of limited benefit
(Figure 7). Consistent with this, pair-wise tests revealed no
significant difference in probe activation between probe doses of
0.387 nmol and 0.775 nmol at all NMDA concentrations. In
addition, pair-wise comparisons of consecutive probe doses higher
Figure 2. Correspondence of an in vivo fluorescent fundus image with an ex vivo retinal flat mount. (A) Fluorescent fundus image
obtained in vivo using the CSLO (28 hours post-probe injection) from a rat eye pretreated with NMDA followed by TcapQ488. Strong, punctate
fluorescent signals were detected in the retina ganglion cell (RGC) layer. (B) Higher magnification of the boxed area in A in which prominent
fluorescent signals are highlighted. (C) Ex vivo flat mount of the same retina showed excellent correspondence with in vivo images in A and B,
indicating that real time images reflect single cell resolution of probe activation. Scale bar: A, 200 mm; C, 100 mm.
doi:10.1371/journal.pone.0088855.g002
Imaging RGC Apoptosis In Vivo with a Peptide Probe
PLOS ONE | www.plosone.org 4 February 2014 | Volume 9 | Issue 2 | e88855
than 0.193 nmol did not reach statistical significance at any
NMDA level with the exception of 0.313 nmol versus 0.387 nmol
at 2.5 mM NMDA (p= 0.016). Figure S2 shows a comprehensive
3-dimensional plot of probe activation as a function of NMDA
concentration and probe dose at all 5 time points.
The frequency of ‘‘background’’ probe activation, as indicated
by PBS-only control injections, also gradually increased with
increasing probe doses and there was a significant difference found
across probe doses in the PBS condition (p,0.0001). This
relationship was not as linear as that seen at each NMDA
concentration (Figure 7). Instead, probe activation frequency in
the PBS condition remained relatively low until probe dose was
increased from 0.313 nmol to 0.387 nmol with pair-wise testing
revealing a significant increase (p = 0.013).
To better evaluate which probe concentration resulted in the
best signal-to-noise ratio at the NMDA concentrations examined,
data from Figure 7 were reanalyzed as fold-increase over PBS across
NMDA and TcapQ488 dose combinations at 12 hours post-probe
Figure 3. Representative kinetics of TcapQ488 activation in vivo. In vivo images were taken in a rat eye pretreated with 12.5 mM NMDA
immediately before (A) and at 4 hours (B), 12 hours (C), 25 hours (D), 48 hours (E) and 72 hours (F) post intravitreal injection of 0.313 nmol TcapQ488.
Evidence of initial probe activation was noted at 4 hours after TcapQ488 injection (B). Scale bar, 200 mm in all images.
doi:10.1371/journal.pone.0088855.g003
Figure 4. Quantitative plot of probe activation from live images. (A) Plot of probe activation from images in Figure 3 B–F. (B) Probe activation
normalized to maximum counts from an individual eye at each time point was averaged across all probe dose/NMDA concentration combinations.
Probe activation increased significantly in the first 12 hours and generally decreased slowly thereafter. Data represent mean 6 SEM.
doi:10.1371/journal.pone.0088855.g004
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injection (Figure 8). Consistent with the findings that TcapQ488
activation began to saturate at probe doses higher than
0.313 nmol and ‘‘background’’ probe activation also increased
significantly at doses higher than 0.313 nmol, a probe dose of
0.313 nmol exhibited the best signal-to-noise ratio, linearity, and
the largest dynamic range across NMDA concentrations. For
lower NMDA concentrations (2.5 and 12.5 mM), which resulted
in less frequent probe activation, the signal-to-noise ratio was
optimized at the lowest probe dose examined (0.097 nmol), but the
overall dynamic range was reduced.
ERG Assessment for Toxicity
ERG analysis consisted of dark-adapted A-wave amplitudes,
dark- and light-adapted B-wave amplitudes, and implicit time
measurements. We performed ERG measurements on eyes
receiving intravitreal injections of PBS or TcapQ488 to assess
for possible retinal toxicity related to probe injection. Since rods
are the dominant photoreceptor subtype in rodents [21], only
dark-adapted B-wave data are presented (Figure 9). Comparison
between pre-injection, 1 week post-injection, and 2 months post-
injection was performed for each probe condition (PBS,
0.193 nmol TcapQ488, 0.387 nmol TcapQ488) (Figure 9A–C).
Statistical analysis of mean B-wave amplitudes revealed a
significant interaction between the three probe conditions and
three time points (p,0.001). There were no significant differences,
however, among probe conditions when tested at each time point
(pre-injection, p = 0.63; 7 days, p= 0.27; 2 months, p = 0.11). The
dark-adapted B-wave showed a mild diminution in amplitude for
each condition at 1 week compared with pre-injection, which
reached significance for PBS (p= 0.010) and 0.387 nmol probe
(p,0.0001), but not for 0.193 nmol probe (p = 0.35). This
decrease continued to be statistically significant at 2 months for
both PBS (p,0.0001) and 0.387 nmol probe (p,0.0001), while
0.193 nmol probe actually showed a significant increase versus
pre-injection (p = 0.004) (Figure 9E). Taken together, these data
were consistent with minimal outer retinal toxicity as a function of
probe concentration, particularly as the effect appears attributable
to the intravitreal injection itself (PBS) rather than probe exposure.
Discussion
Currently, there are several strategies for diagnosing and
monitoring human glaucoma, including intraocular pressure
measurement, perimetric assessment of the visual field, examina-
tion of the optic disc, and assessment of the optic disc and nerve
fiber layer by clinically available imaging devices. These
Figure 5. In vivo probe activation as a function of NMDA
concentration. Rat eyes were pretreated with various NMDA
concentrations (2.5, 12.5, 25, 40 mM) followed by 0.313 nmol
TcapQ488. A control injection consisting of PBS was also performed
to determine background probe activation levels in the absence of
NMDA. All eyes were imaged at 4, 12, 24, 48 and 72 hours post-probe
injection. Probe activation increased with increasing NMDA concentra-
tion at all time points examined. n$3 (5 to 8 eyes) for each time point.
Data represent mean 6 SEM.
doi:10.1371/journal.pone.0088855.g005
Figure 6. In vivo probe signal as a function of TcapQ488 dose.
Rat eyes were pretreated with 25 mM NMDA, followed by various
TcapQ488 doses (0.097, 0.193, 0.313, 0.387 and 0.775 nmol). All eyes
were imaged at 4, 12, 24, 48 and 72 hours post-probe injection. Probe
activation increased with increasing TcapQ488 doses at all but the
earliest time point (4 hours post probe injection). n$3 (5 to 8 eyes) for
each time point. Data represent mean 6 SEM.
doi:10.1371/journal.pone.0088855.g006
Figure 7. Probe activation in vivo as a function of both NMDA
concentration and probe dose. Retinal ganglion cell apoptosis was
induced in rats by intravitreal injection of NMDA at various
concentrations (0 (PBS only), 2.5, 12.5, 25 and 40 mM), followed by
intravitreal injection of TcapQ488 (at 0 (PBS only), 0.097, 0.193, 0.313,
0.387 and 0.775 nmol) for a total of 27 NMDA-probe-dose combina-
tions. Data reflect imaging at 12 hours post-probe injection. Probe
signal increased as both NMDA concentration and probe dose
increased. The plateau in TcapQ488 activation above 0.313 nmol
indicates saturation of the dynamic range of probe dosing. n$3 (5 to
8 eyes) at each combination. Data represent mean 6 SEM.
doi:10.1371/journal.pone.0088855.g007
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approaches for assessing RGCs are limited primarily to identifying
RGC loss and subsequent changes to the field of vision, optic disc,
or nerve fiber layer and therefore fail to provide real-time
information regarding the status of RGCs which may reside in
early injury or pre-death states. Thus, there is a need to improve
our ability to monitor the course of RGC injury in glaucoma to
assess therapy over time with a more facile marker of disease
progression. Molecular imaging with activatable probes provides
one such method and has potential to improve our ability to detect
and monitor apoptotic processes in RGCs over time, guiding
therapeutic choices in the management of this disease. The ability
to monitor RGC status without the delays inherent in current
clinical approaches should serve to reduce the duration and
expense of glaucoma clinical trials and may accelerate the
evaluation of potential neuroprotective agents in both animal
models and human trials.
Use of a cell-penetrating activatable probe for in vivo imaging of
RGC physiology has not been previously reported. Herein,
TcapQ488 detects effector caspase activity signifying apoptotic
cascade activation within a select subset of RGCs in rat retina.
These results confirm our previous ex vivo analysis of retinal flat
mounts using the same NMDA model in rats [18]. Direct
comparison of images in vivo and flat mounts ex vivo from the same
animal showed precise correlation of fluorescence in individual
RGCs, confirming that the focal fluorescence seen on in vivo
imaging faithfully represents our previous findings. Also as noted
previously, the frequency of cells displaying probe activation in vivo
showed the expected dose-response relationship with NMDA. This
finding was now confirmed across multiple probe doses and was
consistent at each concentration studied.
In vivo imaging enables repeated analysis of probe activation in a
single animal across multiple time points post-intravitreal injec-
tion. Using this strategy, we identified a representative time point,
12 hours post injection, at which maximal or near maximal probe
activation occurred. This time point was consistent across probe
and NMDA concentrations and was therefore used for most
analyses. Additional analyses will be required to determine
Figure 8. Signal-to-noise ratio across NMDA concentrations
and TcapQ488 probe doses. TcapQ488 activation data from Figure 7
was normalized to PBS pre-treatment (i.e., NMDA=0) for each probe
dose to reflect relative ‘‘signal-to-noise.’’ For lower NMDA concentra-
tions (2.5 and 12.5 mM), the ratio was highest at 0.097 nmol probe,
while for higher NMDA concentrations (25 and 40 mM), the ratio was
similar from probe doses 0.097 to 0.313 nmol. Data represent mean
normalized labeled cells 6 Error Propagation.
doi:10.1371/journal.pone.0088855.g008
Figure 9. Dark-adapted B-wave amplitudes as a function of probe dose and time post-treatment. Treatment indicates PBS or probe only
injections. (A–C) Comparison among pre-treatment, 1 week post-treatment, and 2 months post-treatment time points for each probe condition (PBS,
0.193 nmol TcapQ488, 0.387 nmol TcapQ488). (D–F) Comparison of each probe condition at each time point (pre-treatment, 1 week and 2 months
post-treatment). There were no significant differences on dark-adapted B-wave amplitudes among probe conditions when tested at each time point.
Data represent mean 6 SD.
doi:10.1371/journal.pone.0088855.g009
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whether the same cells showed evidence of probe activation
throughout the first 72 hours post-probe injection, or whether the
totals represent a flux between ongoing probe activation and
eventual loss of fluorescence in individual RGCs as apoptosis
progresses to completion. The half-life of unactivated probe and
activated probe fluorescence, and the possibility of uptake by
phagocytic cells also require additional study. Given that our
approach results in distinct single-cell fluorescence, it should be
possible in future studies to focus on the fate of individual cells
throughout the duration of fluorescence resulting from probe
activation. This will be critical to understanding whether probe
activation will persist in the presence of a repeated or ongoing
insult, as might occur with elevated intraocular pressure, or
whether repeated injections of probe might be informative.
Rigorous 3-dimensional titration curves of probe activation
were generated based on NMDA concentration, TcapQ488
dosage, and time. This analysis was needed to determine probe
concentrations which would maximize the signal-to-noise ratio,
which is critically important for eventual application of this
strategy in human glaucoma. The use of the lowest probe
concentration possible should reduce the risk, if any, of potential
probe-related retinal toxicity. As anticipated, detection sensitivity
increased with increasing probe dose, but only to a point.
Increasing TcapQ488 dosage above 0.313 nmol provided mini-
mal additional benefits in terms of sensitivity and may increase any
potential probe-related toxicity. Our signal-to-noise analysis
indicated by the ratio of fluorescent labeled cells at each NMDA
and probe dose to that seen in the PBS-only condition, varied with
each of these parameters. As discussed previously [22], the relative
frequency of RGC apoptosis is expected to be much less in human
glaucoma than that observed at the higher concentrations of
NMDA utilized in this analysis. As such, the sensitivity to detect
apoptosis at a relatively low concentration of NMDA (i.e., 5 nmol)
may be of greater importance than that seen at higher
concentrations. In our analysis, the signal-to-noise ratio was
maximized for the two lowest NMDA conditions at a much lower
probe dose. This suggests that for a low apoptosis frequency, the
decreased ‘‘noise’’ offered by a lower dose of probe outweighs the
benefits of increased sensitivity and signal amplification seen at
higher doses.
One distinct advantage of an activatable peptide probe is that
activation and subsequent fluorescence signal should not occur
until intracellular uptake and cleavage by the specific target
enzyme has been initiated. Ideally there should be no probe
activation in the PBS only condition. However, evidence of probe
activation was detected in the absence of NMDA at the higher
probe doses. Several possible mechanisms apply. TcapQ488
activation could reflect a baseline level of RGC apoptosis which
is occurring in the rat retina, although this would be expected to
be relatively infrequent. Probe activation could result from
intravitreal injection-related RGC apoptosis regardless of the
nature of the injectate, being related to the small increase in
intraocular pressure resulting from even the small volumes (2 ml)
utilized in this study [23]. In either case, the frequency of probe
activation in the PBS-only condition would be expected to be
stable across all probe concentrations examined. Since there was a
clear increase in probe activation in the PBS-only condition going
from 0.313 nmol probe to 0.387 nmol, these two factors would
not fully explain our findings. Probe-associated fluorescence could
occur through a concentration-dependent non-specific dequench-
ing of fluorescence not involving true probe activation. Probe
activation could also result from probe-related toxicity causing
apoptosis in a subset of RGCs, resulting in probe activation.
Assuming the vitreous volume of an adult rat eye to be ,56 ml
[24] and the probe volume for the 0.313 nmol dose, the effective
concentration of probe in the vitreous was, 5.5 mM. While below
the previously determined LD50 of 1062 mM from in vitro
experiments with a similar probe [3], a subset of cells may show
toxicity at this dose. Either mechanism could account for the fact
that probe activation under the PBS-only condition was at least
partly probe dose-dependent. Alternatively, the ‘‘background’’
probe activation might reflect a combination of both probe dose-
dependent and -independent effects.
To move our probe toward future clinical usage, physiological
evidence of potential probe toxicity was assayed by electroretino-
gram (ERG). Full-field ERG has been used in both humans and
lower animals as an indicator of retinal function and ERG changes
can provide evidence of retinal injury or toxicity, particularly to
the outer retina [25,26]. Under conditions of dark adaptation, the
A-wave is generally associated with rod photoreceptor activity
while the B-wave is associated with a combination of Muller and
bipolar cell layer activity [27]. While these results do not
specifically address RGC or inner retinal toxicity, they do provide
a means for assessing potential overall retinal toxicity related to the
intravitreal probe injection, particularly at higher probe doses.
Overall, there was little evidence in our ERG analyses to suggest
probe toxicity. Maximal signal-to-noise ratios and linearity
occurred at 0.313 nmol of probe with minor toxicity observed
both by potential autoactivation and B-wave imaging, but
0.193 nmol still yield nearly identical signal-to-noise ratios
(Figure 8), minimal autoactivation, and no observable toxicity
via B-wave imaging.
Several molecular strategies for apoptosis detection have been
developed. One approach exploits the high affinity of annexin V
for phosphatidylserine [28]. This phospholipid is located primarily
in the inner leaflet of the plasma membrane of normal cells and is
externalized to the outer leaflet early in the commitment to
apoptosis [29]. Optical imaging with annexin V-Alexa Fluor 488
has been applied to the retina [30,31]. While of considerable
promise, a fundamental criticism of imaging with annexin V is that
the polypeptide binds to phosphatidylserine regardless of whether
the phospholipid is exposed on the external leaflet or, if accessible,
on the internal leaflet. Cells that undergo necrosis develop defects
in the plasma membrane that enable large molecular weight
molecules like annexin V access to phosphatidylserine residing in
the inner leaflet and thus, in the absence of a second marker of
membrane integrity (e.g., propidium iodide), these labeled
polypeptides do not distinguish apoptosis from necrosis. This
limits diagnostic specificity of the technique by any imaging
modality. Other limiting factors for the general use of annexin V
include rapid serum half-life of the polypeptide, poor penetration
of the blood-brain barrier (and the blood-retinal barrier),
pharmacokinetic complexities related to size, potential for
immunogenicity, and low signal-to-noise ratios for imaging
applications [32,33,34].
Modular probe design as utilized in our approach represents a
distinct advantage. Any or all probe components – targeting
sequence, quencher, fluorophore, and cleavage site – may be
altered to achieve a desired result. Given the preferential uptake by
RGCs of our cell-penetrating peptides as previously demonstrated
[13] and the potential to conjugate them to diverse moieties [17],
may render these CPPs useful for delivering other molecular
imaging probes to RGCs. Alternatively, further modifications to
these CPPs may result in probes with enhanced uptake by other
retinal cell types. While identification of CPPs which cross the
blood-retinal barrier is desirable, intravitreal injection of retinal
therapeutics has become increasingly commonplace in recent
years with a low incidence of adverse events [35] Similarly, while
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TcapQ probes are designed to detect enzymes integral to the
apoptotic cascade, it is clear that this platform will accommodate
specific peptide sequences recognized by other proteases, kinases,
and enzyme activities. As such, our current ‘‘proof of concept’’
experiments should provide the basis for a broad class of novel
imaging agents with applications throughout ophthalmology.
These applications are not limited to imaging, as ‘‘theranostic’’
probes may ultimately be designed with both imaging and
therapeutic capabilities. Identification of important structure-
function relationships is an ongoing process facilitated by our
ability to evaluate next generation probes in both well-established
in vitro [14,16,19] and in vivo (NMDA) models.
The NMDA model employed here is ideal for both the initial
validation and future structure-function analysis of these molecular
imaging probes. The model is well-established, titratable, highly
reproducible, has a relatively short turnover time, and apoptosis
can be largely limited to RGCs. As we move towards further pre-
clinical validation of this and future generation probes, a more
disease-specific animal model of RGC degeneration resulting from
elevated intraocular pressure and more closely mimicking human
glaucoma in terms of the time course and frequency of RGC
apoptosis is desirable. Several such models exist in rodents and
primates and will provide a means for further translation of this
approach towards human application [36]. Our current results will
guide our choice of probe concentration and imaging intervals
going forward into more advanced glaucoma-specific models.
Supporting Information
Figure S1 Comparison of manual fluorescent RGC cell
counting versus automated cell enumeration using
ImageJ. Images at 4, 12, 24, 48, and 72 hours post probe
injection were analyzed by manually counting fluorescent cells
using Image J software. Fluorescent cell counts were based on
fluorescence intensity and sharpness in a group of animals (n = 6)
treated with 25 nmol NMDA and 0.313 nmol TcapQ488. The
same images were analyzed using the automated counting
program ‘‘Find Maxima’’ in ImageJ (http://rsb.info.nih.gov/ij).
Noise tolerance was set to 17, edge and center (optic disc) maxima
were excluded from the analysis field. Fluorescent cell numbers
derived from each method are plotted as a function of probe
injection time. Data represent mean 6 SD.
(TIF)
Figure S2 Comprehensive 3-dimensional plot of probe
activation in vivo as a function of NMDA concentration
and probe dose at five time points post-injection.
(TIF)
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